Trial reportTranslational psychiatry2013
Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo.
Trial report in Translational psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.
- Metabolomics in Depression: What We Learn from Preclinical and Clinical Evidences.Molecular neurobiology · 2025Pooled it
- Can targeted metabolomics predict depression recovery? Results from the CO-MED trial.Translational psychiatry · 2019Trial
- The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: effects of estradiol and progesterone addback.Translational psychiatry · 2017Trial
- Amino Acid-Fatty Acid Profile as a Novel Predictive Method in the Assessment of Diagnosis and Treatment Efficacy of Anxiety-Related Disorders and Mood Disorders.International journal of molecular sciences · 2026Review
- Metabolomic Profiling of Extracellular Vesicles Reveals Distinct Metabolic Dysregulation and Treatment-Specific Signatures in Depression.Biomolecules · 2026Article
- Metabolic differences in female adolescents with obsessive-compulsive disorder and trichotillomania: insights from plasma untargeted metabolomic analysis.BMC psychiatry · 2026Article
- The evolution of SSRI research: trajectories of knowledge domains across four decades.BMC psychiatry · 2026Article
- Hyperuricemia in Chinese Patients with Mood Disorders: Prevalence, Related Factors, and Predictive Model.Neuropsychiatric disease and treatment · 2025Article
- Dispositional Optimism Predicts Antidepressant Treatment Response in Major Depressive Disorder: Potential Relevance for Positive Psychology Interventions.The journal of positive psychology · 2024Article
- The Association Between Branched-Chain Amino Acid Concentrations and the Risk of Autism Spectrum Disorder in Preschool-Aged Children.Molecular neurobiology · 2024Article
- Citalopram exposure of hESCs during neuronal differentiation identifies dysregulated genes involved in neurodevelopment and depression.Frontiers in cell and developmental biology · 2024Article
- Circulating metabolites may illustrate relationship of alcohol consumption with cardiovascular disease.BMC medicine · 2023Article
- Pharmacokinetics in Pharmacometabolomics: Towards Personalized Medication.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Metabolomic and inflammatory signatures of symptom dimensions in major depression.Brain, behavior, and immunity · 2022Article
- Review
- The Antidepressant Effect of Deoiled Sunflower Seeds on Chronic Unpredictable Mild Stress in Mice Through Regulation of Microbiota-Gut-Brain Axis.Frontiers in nutrition · 2022Article
- A Preliminary Nuclear Magnetic Resonance Metabolomics Study Identifies Metabolites that Could Serve as Diagnostic Markers of Major Depressive Disorder.Current neuropharmacology · 2022Article
- Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report.Communications biology · 2021Article
- Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression.Translational psychiatry · 2021Article
- Metabolic features of recurrent major depressive disorder in remission, and the risk of future recurrence.Translational psychiatry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we characterized early biochemical changes associated with sertraline and placebo administration and changes associated with a reduction in depressive symptoms in patients with major depressive disorder (MDD). MDD patients received sertraline or placebo in a double-blind 4-week trial; baseline, 1 week, and 4 weeks serum samples were profiled using a gas chromatography time of flight mass spectrometry metabolomics platform. Intermediates of TCA and urea cycles, fatty acids and intermediates of lipid biosynthesis, amino acids, sugars and gut-derived metabolites were changed after 1 and 4 weeks of treatment. Some of the changes were common to the sertraline- and placebo-treated groups. Changes after 4 weeks of treatment in both groups were more extensive. Pathway analysis in the sertraline group suggested an effect of drug on ABC and solute transporters, fatty acid receptors and transporters, G signaling molecules and regulation of lipid metabolism. Correlation between biochemical changes and treatment outcomes in the sertraline group suggested a strong association with changes in levels of branched chain amino acids (BCAAs), lower BCAAs levels correlated with better treatment outcomes; pathway analysis in this group revealed that methionine and tyrosine correlated with BCAAs. Lower levels of lactic acid, higher levels of TCA/urea cycle intermediates, and 3-hydroxybutanoic acid correlated with better treatment outcomes in placebo group. Results of this study indicate that biochemical changes induced by drug continue to evolve over 4 weeks of treatment and that might explain partially delayed response. Response to drug and response to placebo share common pathways but some pathways are more affected by drug treatment. BCAAs seem to be implicated in mechanisms of recovery from a depressed state following sertraline treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.